Board of Directors

Consulting projects have included evaluation of business strategies and potential acquisitions, executive mentoring, and business/financial due diligence for investment opportunities. Recent board and executive officer roles include the Bako Medical Education Foundation, BPA Holding Corp., the Wexford Plantation Charitable Foundation, the Wexford Plantation Homeowners’ Association and various club organizations.

At Ampersand, Sue was a Partner on the firm’s investment team with responsibility for the execution and monitoring of the firm’s portfolio company investments. In this role, Sue led diligence efforts for new and follow-on investments and acquisitions, oversaw the transitioning of new companies into Ampersand’s portfolio, and assisted in the execution of sales and other liquidity events. Sue served as interim CFO of a number of Ampersand portfolio companies, working directly with management teams to stabilize and improve financial and operating performance. She served on the boards and board committees of numerous publicly traded and private companies during her tenure at the firm.

With over thirty years of experience in the technology and related industries, Sue built and led teams of early- and later-stage private and public companies, with a focus on developing profitable growth strategies. Prior to joining Ampersand, she served as Executive Vice President & Chief Financial Officer of Moldflow Corporation, a global engineering software company. During her tenure, she led the successful IPO of Moldflow’s shares on NASDAQ, was responsible for execution of key acquisitions, and helped architect strategies to grow the company’s global revenues and presence more than fivefold.

Before joining Moldflow, Sue was Chief Financial Officer and held senior finance positions in high technology companies in the Boston area. She began her career with a predecessor firm of PricewaterhouseCoopers, is a CPA and holds a Bachelor of Science degree in Business Administration from Stonehill College. Sue currently resides in Hilton Head Island, SC.

He has been a member of the of the FACFS and a Diplomate of the American Board of Podiatric Surgery. Dr. Berlin entered practice in Baltimore as a member of Podiatry Associates, a group practice which grew to 16 doctors during his association with the firm.

He founded Podiatric Pathology Laboratories in 1978 and was President until it was acquired by Quest Diagnostics in 1995. His activities as a Podiatrist are many, having served as the past President of a number of organizations including the Maryland Podiatric Medical Association, the American Society of Podiatric Dermatology, and the Fund for Podiatric Medical Education. Dr. Berlin also served as the Podiatric Residency Director at Bon Secours Hospital in Baltimore.

Dr. Berlin has received numerous awards and recognitions, and has lectured extensively on podiatric pathology. He is a past board chairman and member of the Ohio College of Podiatry Board of Trustees and is a member of the OCPM Foundation for Podiatry. He currently is the medical director of Ogenix Corp. where he is involved in treating chronic wounds. He is also actively involved in an aviation company flying organ transplants along the east coast, among his many other interests.

He completed his residency in specialized foot and ankle surgery at the Monsignor Clement Kern Hospital in Detroit, MI and later practiced general podiatric medicine and surgery in Elizabeth, NJ. He earned board certification by the American Board of Podiatric Surgery, the American Board of Primary Podiatric Medicine and Orthopedics, and the American Board of Wound Management.

Dr. Nelson is certified phlebologist, competent in saphenous and perforator vein ablation and sclerotherapy.  He served on the surgical staff of Memorial General Hospital and Alexian Brothers Hospital in Elizabeth, NJ.

Additionally, he served as Director of Podiatric Medical Education and chief of Podiatry at East Orange General Hospital.  Dr. Nelson taught as a clinical instructor of anatomy and physiology at the Orange Memorial Hospital School of Nursing. He served as residency director, professor, Associate Dean of Clinics and Dean at Barry University School of Podiatric Medicine in Miami from 1988 through 2013. Dr. Nelson continues to teach courses in clinical pharmacology, peripheral vascular disease, Anatomy and Pathophysiology at the Broward College School of Nursing and Podiatric Medicine.

David has led the legal work on well more than 100 acquisitions, spin-outs, dispositions, mergers, and follow-on transactions, and has represented more than 50 operating companies across a wide range of healthcare and life sciences, including drug development, contract research (CROs), contract manufacturing (CDMOs), device, component and instrument manufacture, development and clinical testing laboratories, tissue engineering and gene sequencing and synthesis vendors. His work includes commercial transactions, board support, employee matters, dispute resolution, real estate, financings and licensing.

Prior to establishing his law practice, David served as General Counsel to Ampersand Capital Partners from 2005 to 2011, and to several Ampersand portfolio companies and non-Ampersand companies. Previously, David was General Counsel of ArQule (Nasdaq: ARQL), where he also served as Chief Compliance Officer. Prior to ArQule, David served as the business lawyer for the Biomedical Services division of the American Red Cross. David’s work for the $1.5 billion revenue Blood, Plasma and Tissue divisions of the Red Cross focused on international joint ventures, licensing, M&A, and commercial agreements. Prior to joining the Red Cross, David practiced in the fields of tax and international transactions at prestigious law firms in New York and Jerusalem. David holds a J.D. from Columbia Law School as a Harlan Fiske Stone Scholar, an M.A. with distinction in Talmud from the Jewish Theological Seminary and a B.A. from Columbia (Middle East studies).